Generic Name and Formulations:
Palonosetron (as HCl) 0.075mg/1.5mL, 0.25mg/5mL; IV inj; contains mannitol.
Indications for ALOXI:
Prevention of acute nausea and vomiting due to initial and repeat courses of moderately and highly emetogenic chemotherapy in adults. Prevention of delayed nausea and vomiting due to initial and repeat courses of moderately emetogenic chemotherapy in adults. Prevention of acute nausea and vomiting due to initial and repeat courses of emetogenic chemotherapy, including highly emetogenic cancer chemotherapy, in children 1 month–<17yrs. Prevention of post-op nausea and vomiting for up to 24hrs after surgery in adults.
≥17yrs: give 30 mins prior to chemotherapy. 0.25mg IV as a single-dose over 30 secs. Post-op: give immediately before anesthesia induction. 0.075mg IV over 10 secs.
<1 month: not established. 1 month–<17yrs: give 30 mins prior to chemotherapy. 0.02mg/kg IV as a single-dose over 15 mins; max 1.5mg/dose.
Pregnancy (Cat.B). Nursing mothers: not recommended.
Selective 5-HT3 receptor antagonist.
Headache, constipation, bradycardia, QT prolongation, diarrhea, dizziness, tachycardia, hypotension.
Single-use vial (0.075mg/1.5mL)—5; (0.25mg/5mL)—1
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|